Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLANCTON trial of early intravenous omega-3 fatty acids in predicted severe acute pancreatitis
2022-000474-26Phase 3Active
- Sponsor
- Radboudumc
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of eicosapentaenoic acid + docosahexaenoic acid in acute pancreatitis (AP) (2 arms), sponsored by Radboudumc. Primary endpoint: Primary composite endpoint. Started Mar 2022; status: active.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
acute pancreatitis (AP)
Beyond the preview
Go deeper on 2022-000474-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000474-26.